Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
The global pandemic of drug sensitive tuberculosis (TB) as well as the increasing threat from various multidrug resistant forms of TB drives the quest for newer, safer, more effective TB treatment options. The general lack of success in progressing novel chemical matter from high throughput screens of Mycobacterium tuberculosis (M.tb) biochemical targets has prompted resurgence in interest and efforts in prosecuting mycobacterial phenotypic screens. Whole cell active compounds identified from such screens offer significant intrinsic advantages over biochemical screening hits, and derivatives of many of these have proven invaluable in helping to fill the current TB drug development pipeline. Modern techniques for "de-orphaning" such screening hits (i.e., determining their specific biological mechanism of action) offer the possibility of ultimately identifying improved next-generation chemical series by screening these essential, pharmacologically validated biochemical targets as well.
Global Alliance for TB Drug Development (TB Alliance) , 40 Wall Street, 24th Floor, New York, New York 10005, United States.
Christopher B
CB
Cooper
D000995:Antitubercular Agents / Q000737:chemistry / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D015394:Molecular Structure; D058990:Molecular Targeted Therapy / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D014376:Tuberculosis / Q000469:parasitology / Q000517:prevention & control*
D000995:Antitubercular Agents